Showing results (61-70 of 88) with videos related to
Sort By:
Pageof 9
Science Translational Medicine|February 8, 2013
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancerGanapati V Hegde, Cecile C de la Cruz, Cecilia Chiu, et al.Nature Medicine|February 14, 2017
Molecular definition of a metastatic lung cancer state reveals a targetable CD109-Janus kinase-Stat axisChen-Hua Chuang, Peyton G Greenside, Zoë N Rogers, et al.Biorxiv : the Preprint Server for Biology|November 24, 2025
STING activation reshapes the tumor microenvironment leading to tumor regression in osteosarcomaElizabeth P Young, Christine A Johnson, Alex G Lee, et al.Oncotarget|May 19, 2016
Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse modelTsion Zewdu Minas, Didier Surdez, Tahereh Javaheri, et al.Nature Communications|February 22, 2017
An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancerAdrian Vallejo, Naiara Perurena, Elisabet Guruceaga, et al.Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.Cancer|July 30, 2019
Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology GroupRyan D Roberts, Michael M Lizardo, Damon R Reed, et al.Frontiers in Oncology|March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial CancerDivya Natesan, Li Zhang, Henry J Martell, et al.The Journal of Clinical Investigation|December 25, 2019
The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreasKarmele Valencia, Oihane Erice, Kaja Kostyrko, et al.Cancer Research|March 11, 2026
FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor TherapyDaniel E Gracilla, Shruti Menon, Marcus R Breese, et al.Pageof 9